Objective: To establish the efficacy, safety and tolerability of medical cannabis in children with complex motor disorders (CMD).
Methods: The pilot study is prospective and has been approved by the Helsinki ethics committee. Two products of cannabidiol (CBD) enriched 5 % oil formulation of cannabis were compared: the ratio of delta-9- tetrahydrocannabinol (THC) to CBD is 1 to 6 and 1 to 20. These products are supplied by Tikun Olam – a licensed grower based in Tel Aviv. Patients aged 1 to 18 years with CMD are enrolled.